UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. 12390 El Camino Real 92130 San Diego (Zip Code) California (Ad ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q2 2023 Earnings Conference Call August 8, 2023 4:30 AM ET Company Participants Tram Bui - VP, IR and Corporate Communications Helen Torley - President and CEO Nicole LaBrosse - CFO Conference Call Participants Mohit Bansal - Wells Fargo Michael DiFiore - Evercore ISI David Risinger - Leerink Partners Jason Butler - JMP Securities Mitchell Kapoor - H.C. Wainwright Mack Chandler - Jefferies Caroline Palomeque - Berenberg Capital Markets Operator Good afternoon, my n ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ____________ ...

NASDAQ: HALO May 2023 Forward Looking Statements Non-GAAP Financial Measures: Note: This presentation contains product names, trademarks and registered trademarks that are property of their respective owners. | --- | --- | --- | |-------------------------------------------------------------------------|--------------------------------------------------------|-------------------------------------------| | ENHANZE ® | Drug Delivery Platform Technologies \nAuto-Injectors | Commercial Portfolio \nSpecialty Prod ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q1 2023 Earnings Conference Call May 9, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Helen Torley - President and Chief Executive Officer Nicole LaBrosse - Chief Financial Officer Conference Call Participants Na Sun - JPMorgan Corinne Jenkins - Goldman Sachs Mohit Bansal - Wells Fargo Michael DiFiore - Evercore ISI Roy Buchanan - JMP Securities David Risinger - SVB Securities Caroline Palomeque - Ber ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 ___________________________ HALOZYME THERAPEUTICS, INC. (Exact name of registrant as specified in its charter) ___________ ...

• 13-20% YoY growth • Excludes impact of future share repurchases | --- | --- | --- | --- | --- | |---------------|---------|-----------------|-------|--------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------| | | | | | | | Total Revenue | $660.1M | $815M ...

NASDAQ: HALO February 21, 2023 In addition to historical information, the statements set forth in this presentation include forward-looking statements including, without limitation, statements concerning the Company's expected future financial performance (including the Company's financial outlook for 2023) and expectations for profitability, revenue (including expectations for future royalties, milestones and product sales), EBITDA and earnings-per-share, and the Company's plans to repurchase shares under ...

Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2022 Earnings Conference Call February 21, 2023 4:30 PM ET Company Participants Tram Bui - Vice President, Investor Relations and Corporate Communications Dr. Helen Torley - President and CEO Nicole LaBrosse - Chief Financial Officer Conference Call Participants Mohit Bansal - Wells Fargo Mike DiFiore - Evercore ISI Jason Butler - JMP Securities Jessica Fye - JPMorgan Corinne Jenkins - Goldman Sachs Vikram Purohit - Morgan Stanley Dan Tarjan - SVB Securities Oper ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (State or other jurisdiction of incorporation or organization) (I.R.S. Employer Identification No.) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number 001-32335 HALOZYME THERAPEUTICS, INC. (Exact nam ...